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Cutaneous Larva Migrans in Travelers: Synopsis of Histories, Symptoms, and 
Treatment of 98 Patients 
T. Jelinek, H. Maiwald, H. D. Nothdurft, and T. Löscher From the Department of Infoetiol/s Diseases and Tropieal Medicine. 
University Hospital. Universit)' of MI/nieh. MI/nieh. German)' 
The symptoms, medical history, and treatment of 98 patients with cutaneous larva migrans 
(creeping eruption) who attended a travel-related-disease clinic during aperiod of 4 years are 
reviewed. This condition is caused by skin-penetrating larvae of nematodes, mainly ofthe hook-
worm Ancylostoma braziliense and other nematodes of the family Ancylostomidae. Despite the 
ubiquitous distribution of these nematodes, in the investigated group only travelers to tropical 
and subtropical countries were affected; 28.9% of the patients had symptoms for > 1 month, and 
for 24.5% the probable incubation period was> 2 weeks. The efHorescences typically were on the 
lower extremities (73.4% of alliocations). The buttocks and anogenital region were affected in 
12.6% of all locations, and the trunk and upper extremities each were affected in 7.1 %. Only a 
minority of patients presented with eosinophilia or an elevated serum level of IgE. No other 
laboratory data appeared to be related to the disease. Therapy with topical thiabendazole was 
successful for 98% of the patients. Systemic antihelmintic therapy was necessary in two cases 
because of disseminated, extensive infection. 
The syndrome of cutaneous larva migrans develops when 
certain skin-penetrating larvae migrate into the dermis and 
cause distinct symptoms. These are mainly characterized by 
tunnel-like migrating erythemas with severe pruritus. The 
name creepillg eruption is derived from these signs. Usually 
the causative agents are larvae of animal parasites, which 
infect humans (as an abnormal host) without reaching sexual 
maturity. Following penetration, the larvae stay in the stra-
tum germinativum. The active production and secretion of 
hyaluronidase seem to render the movements of the larvae 
possible [I]. Usually a typical dermatitis with vesiculae, pa-
pules, and desquarnations develops within a few days [figure 
I]. The typical erythema occurs 3-4 cm away from the pene-
tration site. The larva itself is usually 1-2 cm ahead of the 
creeping eruption. Within weeks or sometimes months of 
invasion, the larva dies and is resorbed [2]. The infection is 
usually restricted to the skin. In rare cases invasion of the 
lungs, followed by the development of a pulmonary eosino-
philic infiltrate and the presence oflarvae in lavage fluid, has 
been reported [3-5]. 
Most common is infection by the larvae of Ancylostoma 
bra::iliense. a ubiquitous hookworm found in dogs, cats, and 
other mammals. Ancvlostoma caninul1l and Uncinaria steno-
cephala. other hookworms parasitic in dogs and cats, can also 
cause cutaneous larva migrans [4, 6, 7]. From animal feces 
the eggs are passed into the soil, where the larvae hateh. They 
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initially feed on soil bacteria, molt twice before the infective 
third stage, and penetrate through the skin of the new host 
[4, 6, 7]. All unprotected parts of the body in contact with 
the soil are at risk. On rare occasions the disease might be 
caused by Gnathostoma spinigerum, a nematode endemie in 
Asia; Dirofilaria species; and Strongyloides procyonis, a para-
si te of raccoons [6-8] that is thought to be responsible for the 
seasonal "duckhunters' itch" among North American 
hunters [7]. Creeping eruption is usually a pathognomonic 
sign of cutaneous larva migrans. Important differential diag-
noses are larva currens, visceral larva migrans, myiasis, sca-
bies, and the erythema migrans of Lyme disease [8, 9]. 
The objective ofthis investigation was to gain information 
about the regions where cutaneous larva migrans is most fre-
quently acquired by German travelers; about the character, 
on set, and duration of symptoms; and about treatment be-
fore presentation. Furthermore, data concerning the immu-
nologie reaction ofthe patients were inc1uded in the analysis 
whenever available. 
Methods 
Of 13,300 patients visiting the travel-related-disease c1inic 
ofthe University ofMunich between January 1990 and Oc-
tober 1993, 11 % presented with skin symptoms. Cutaneous 
larva migrans was diagnosed c1inically in 98 patients (6.7% of 
the patients with skin symptoms). The charts of all 98 pa-
tients were reviewed in regard to medical history, symptoms, 
and therapy. All patients were German nationals returning 
from vacations abroad; 54 (55. 1%) were male, and 44 
(44.9%) were female. The majority (74.5%) were aged 21-40 
years (mean, 32 years). Laboratory methods used were para-
sitological stool investigations (Merthiolate [thimerosal]-
iodine-formalin concentration; MIFC) [10], determinations 
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Figure 1. This photograph of the foot of a patient with cutane-
ous larva migrans illustrates the typical skin signs associated with 
creeping eruption . 
oflevels of eosinophiles and total serum IgE, and ELlSAs for 
antibodies to Toxocara canis (excretory/secretory antigens) 
[11], Dirofilaria ill1l11ili5. and Onchocerca 1'0"'11/115 (adult 
worm antigens) [12] . 
Results 
Duration of the patients' travel varied from I to 72 weeks 
(mean, 6 weeks). Of their destinations, Southeast Asia 
c1early headed the list (31 patients [31 .6%]), followed by the 
Caribbean (19 [19.4%]), South America (13 [13.4%]), East 
Africa and the Indian subcontinent (10 [10.2%] each), Cen-
tral America (8 [8 .2%]), and West Africa (5 [5.1 %]). There 
was a markedly low incidence of travel to South and North 
Africa (I (I %] each) (figure 2). 
For 53 patients (54.1 %). no exact data were available re-
garding the duration oftheir symptoms. Ofthe remaining 45 
patients, 28.9% reported having symptoms for > I month, 
and one patient's symptoms lasted 9 months (range, 1-36 
Figure 2. This map indicates 
areas ofthe world to which 98 pa-
tients with cutaneous larva mi-
grans had traveled prior to the 
onset of their symptoms: South-
east Asia (31.6%). the Caribbean 
or Central America (27.6%). 
South America (13.4%). East 
Africa and the Indian subconti-
nent (10.2% each). West Africa 
(5.1 %). and South Africa and 
North Africa ( 1 % each). 
weeks; mean , 5.6 weeks). Of the 98 patients, 75.5% pre-
sen ted with the typical symptoms of creeping eruption 
within 4 weeks of returning from their journey, and 24.5% 
were seen >4 weeks after returning (range, 1-36 weeks; 
mean , 5 weeks); in two of the latter cases. presentation oc-
curred 9 months after return. From the available data, the 
time of onset of symptoms could be determined for 45 pa-
tients. Two patients' symptoms began 7 months after their 
return. The time of onset ranged from 16 weeks before return 
from the journey to 28 weeks after return (mean, 1.5 days 
after return). 
In all cases the diagnosis was established instantly from 
the ca se history and typical symptoms. Twenty-two patients 
presented with cutaneous larva migrans in more than one 
area ofthe body. The lower extremities were affected in most 
cases (73.4% of all locations): eruptions on the feet repre-
sen ted 61.7% of alliocations; on the lower legs, 3.1 %; and on 
the upper legs, 8.6%. Eruptions on the buttocks and/or ano-
genital region represented 12.6% of alliocations; these erup-
tions were usually in areas typically covered by bathing suits 
(figure 3). Creeping eruptions on the trunk represented 7.1 % 
ofalliocations, and eruptions ofthe upper extremeties repre-
sen ted another 7. 1 % (most of the latter eruptions occurred in 
small children) (figure 4). Symptoms did not involve the 
head, but in rare ca ses such symptoms have been described 
in the literature [13]. 
Laboratory findings played no role in the establishment of 
the diagnosis. Only 20% ofthe 40 patients tested had eosino-
philia, defined as an eosinophil proportion of;,. 7% of the 
leukocyte count (eosinophil proportion range, 0%-37%; 
mean , 5%). The total serum level ofIgE, which was measured 
in 13 patients. ranged from 13 to 4,000 IU/mL (mean, 539 
IU/mL); six patients had IgE levels >200 IU/mL, but the 
majority (seven patients) had levels below this mark . Ele-
vated titers of antibodies to the T. canis ES-antigen were 
demonstrated in four of 10 patients tested; factors (multiples 
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Figure 3. Severe creeping eruption was noted on the buttocks of 
a patient with cutaneous larva migrans who had recently returned 
from Southeast Asia. 
ofnormal activity) ranged from negative values to 41 (mean 
factor. 12). Significant titers of filarial antibodies were de-
tected in only one of 18 patients tested. Stool analysis was 









Figure 4. This model shows the distribution (percentages per 10-
cation) of skin symptoms in 98 patients with cutaneous larva mi-
grans. 
Table 1. Treatment received by 22 patients with cutaneous larva 
migrans before presentation at the hospital clinic. Some patients 
received more than one type of treatment. 
Agent or method oftreatment 
Thiabendazole ointment 
Soap 









Antibiotic ointments plus 
steroid ointments 













At presentation. 22 (22.4%) of the patients had already 
received some kind of treatment. Frequently. several meth-
ods had been alternated or used simultaneously in the treat-
ment of a patient (table I). Altogether. 12 different methods 
of treatment were used. Most commonly. nonspecific oint-
ments were prescribed. For six patients. cryotherapy (with 
repeated use offtuid nitrogen) was used in an attempt to kill 
the larvae. This method was unsuccessful for all patients and 
resulted in severe blistering or ulceration of the skin of two 
patients. Just as unsuccessful were surgical intervention (3 
patients). locally applied antiscabiotic ointments (2 pa-
tients). and oral mebendazole (2 patients). Four patients had 
received thiabendazole ointment for local application. In 
these cases the symptoms. notably the itching. had usually 
already ceased. At the travel-related-disease c1inic. all 98 pa-
tients were treated with thiabendazole ointment applied 10-
cally. In all cases we used a special preparation of 15% thia-
bendazole and 3% salicylic acid in unguentum alcoholum 
lanae. The use of oral antihelmintic agents as weil was indi-
ca ted for two patients with disseminated. extensive infection; 
in one case we prescribed a single dose ofalbendazole. in the 
other a single dose of thiabendazole. No side effects were 
noted. The therapy was successful for 96 patients (98%) 
within 10 days. In one case treatment had to be extended to 
2 weeks. and in another case to 4 weeks. before the lesions 
disappeared. 
Discussion 
Despite the ubiquitous distribution of A. braziliense and A. 
caninum. cutaneous larva migrans seems to be restricted 
mainly to tropical and subtropical countries. There have 
been re ports about autochthonous infections in northern c1i-
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mates, but these cases seem to be rare [2, 4, 6, 7], as was 
indicated by the results of our investigation. None of the 
investigated patients had acquired infection at any of the 
destinations more popular among European tourists, in the 
northern and eastern Mediterranean, despite the fact that A. 
braziliense and other nematodes ofthe Ancylostomidae fam-
ily are quite endemic in these areas [8]. However, only 2.2% 
of our total patient population had traveJed to Mediterran-
ean countries before referral. This might present a consider-
able bias for speculations about the frequency of larva mi-
grans infection in these areas. 
In the investigated series ofpatients, the course ofcutane-
ous larva migrans frequently was chronic; 28.9% of the pa-
tients for whom such data were available reported that the 
duration of symptoms was> I month, and for one patient it 
was 9 months. These patients frequently had received 
various nonspecific treatments, often with fluid nitrogen, 
which had obviously not shortened the course of disease. 
The probable incubation period was estimated by caJcu-
lating the difference between the time ofreturn to Germany 
and the time of onset of symptoms. This method might have 
led to underestimations in some cases, because it imputes the 
time of infection to the last day of the journey. Even so, for 
24.5% the probable incubation period was >2 weeks, while 
those reported in the literature vary from minutes to a few 
days [2, 6, 7]. Two patients developed symptoms 7 months 
after returning from their journey. The possibility that infec-
tion occurred in Germany should be considered in these 
cases. It cannot be excJuded completely, although case re-
ports ofinfections in northern cJimates are rare [4, 6]. How-
ever, considering the high percentage of our patients for 
whom the onset of symptoms was delayed, we favor the 
theory that infection occurred during the journey, especially 
since none ofthe patients mentioned extensive exposure to 
possibly contaminated soil in Germany. 
The frequency with wh ich the buttocks, anogenital region, 
trunk, and upper extremities were affected is notable. It 
seems likely that the patients whose buttocks and genitalia 
were affected were nude in the sand for some time. It is nota-
ble that the upper extremities were affected more often in 
children than in adults. The most likely explanation for this 
phenomenon is that these areas in small children frequently 
are exposed to soil for extended periods. 
The differentiation between scabies and cutaneous larva 
migrans is not always easy, especially if the latter presents 
with atypical effiorescences on the upper extremities. Impor-
tant diagnostic criteria for scabies are the following: a history 
of exposure to surroundings possibly infested by the mite 
Sarcoptes scabiei; crustaceous lesions, papules, generalized 
itching, and rash; microscopic demonstration of S. scabiei. its 
eggs, or its feces in skin scrapings; involvement ofthe hands; 
and the appearance of multiple lesions. In cases of cutaneous 
larva migrans, the appearance of single migrating tracts and 
vesicular lesions, involvement of the legs rather than the 
hands, and rapid cessation ofsymptoms after the use ofthia-
bendazole ointment are important diagnostic cJues. 
Dur data did not confirm that eosinophilia and a rise in the 
total serum titer of IgE are typical signs of cutaneous larva 
migrans as they are in systemic helminthic infections [2, 4]. 
Perhaps the presentation of antigen to the immune system is 
limited in infections that usually are confined to the skin. 
The overwhelming majority of our laboratory results were 
within the normal range. Therefore, the diagnosis of cutane-
ous larva migrans seems to rely solelyon cJinical findings. 
Laboratory findings might support the diagnosis but usually 
cannot prove it. 
Surgical therapy was attempted for three patients, in all 
cases without success. Since the larva is situated 1-2 cm 
ahead ofthe visible track, it cannot be localized reliably and 
therefore can only rarely be removed by a knife [2, 4]. Cryo-
therapy with the application of fluid nitrogen led to blisters 
and chronic uJcerations in two ofthe six patients treated by 
this method, and subsequently all six patients' creeping erup-
tions were still spreading. This finding underlines the fact 
that the larvae are capable of surviving temperatures as low 
as -21°C for > 5 minutes [8]. Therefore, we do not recom-
mend cryotherapy for treatment of cutaneous larva migrans, 
although the group treated in this way is too sm all to allow 
statistical analysis. 
For 98% of the investigated patients, cure was achieved 
within 10 days by the topical application of thiabendazole 
ointment only. For two patients with extensive, dissemi-
nated infections, treatment with single oral doses ofthiaben-
dazole and albendazole was preferred [13-17]. The fre-
quently severe itching ceased rapidly for all patients 
following the application of antihelmintic agents. These re-
sults demonstrate the excellent efficacy of topically applied 
thiabendazole in the treatment of cutaneous larva migrans. 
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